AOD-9604 Post-COVID and Long-COVID Recovery Protocol

What Is AOD-9604 and Why Are Practitioners Considering It for Long-COVID?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to residues 176 to 191 of the C-terminal region of human growth hormone. Researchers isolated this fragment specifically because it retains hGH's lipolytic and anti-lipogenic properties without the insulin-desensitizing or IGF-1-elevating effects of full-length hGH. Obesity and metabolic researchers first studied it as an anti-obesity compound, with a phase IIb trial (ClinicalTrials identifier NCT00310791) demonstrating dose-dependent fat loss at 1 mg/day oral dosing [1].

Long-COVID, formally defined by the World Health Organization as symptoms persisting more than 12 weeks after confirmed or probable SARS-CoV-2 infection, affects an estimated 10 to 20% of infected individuals [2]. Signature pathophysiology includes mitochondrial dysfunction, persistent low-grade inflammation, microbiome disruption, and autonomic nervous system dysregulation. These overlapping mechanisms are the rationale practitioners cite when considering peptides like AOD-9604.

The Mitochondrial Dysfunction Angle

Mitochondrial respiratory chain impairment is documented in long-COVID patients. A 2023 study published in Nature Communications (N=39 long-COVID patients vs. 39 controls) found significantly reduced mitochondrial membrane potential and ATP production in peripheral blood mononuclear cells [3]. Growth hormone secretagogues and hGH fragments may support mitochondrial biogenesis through IGF-1-independent pathways, though this has not been tested with AOD-9604 specifically in human populations.

The Inflammation and Immune Dysregulation Angle

Elevated IL-6, TNF-alpha, and persistent complement activation are common in long-COVID [4]. Animal data suggest AOD-9604 may modulate inflammatory signaling through beta-3 adrenergic receptor pathways in adipose tissue, reducing pro-inflammatory adipokine secretion. Whether this translates to systemic cytokine reduction in post-viral illness remains untested in controlled trials.

Evidence-Level Summary

Practitioners should understand the hierarchy here clearly. The metabolic and anti-obesity data for AOD-9604 reach phase IIb in humans [1]. The long-COVID application is entirely off-label, supported only by mechanistic plausibility and anecdotal clinician reports. No peer-reviewed RCT, cohort study, or case series has been published specifically on AOD-9604 in SARS-CoV-2 sequelae as of January 2025.

Long-COVID Pathophysiology Relevant to AOD-9604 Prescribing

Understanding which long-COVID mechanisms AOD-9604 might address helps set realistic expectations for both patient and clinician. Long-COVID is not a single disease. The WHO clinical case definition recognizes symptom clusters spanning fatigue, cognitive impairment, dyspnea, autonomic dysfunction, and pain [2].

Mitochondrial and Metabolic Impairment

Skeletal muscle biopsy data in long-COVID patients show type II fiber atrophy, reduced oxidative capacity, and abnormal mitochondrial morphology [5]. These findings overlap substantially with findings in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). AOD-9604's proposed role here is indirect: by reducing ectopic fat deposition and potentially supporting GH-receptor signaling in muscle, it may create a more favorable metabolic substrate for mitochondrial recovery. The mechanism is speculative without direct human trial data.

Neuroinflammation and Cognitive Symptoms

Brain fog affects roughly 22% of long-COVID patients at six months in the REACT-2 study (N=508,707 adults, UK) [6]. Neuroinflammatory markers including microglial activation and blood-brain barrier disruption are documented on PET imaging in subsets of patients. AOD-9604 does not cross the blood-brain barrier in meaningful concentrations based on current pharmacokinetic modeling, so direct CNS effects are unlikely. Cognitive benefits reported anecdotally may reflect downstream improvement in systemic inflammation or energy metabolism rather than direct neurotropic action.

Immune Dysregulation and Persistent Viral Antigen

A subset of long-COVID patients carries detectable SARS-CoV-2 spike protein in plasma up to 12 months post-infection [7]. This persistent antigen load drives T-cell exhaustion and aberrant innate immune activation. AOD-9604 has no established antiviral mechanism. Practitioners combining it with other peptides such as thymosin alpha-1 or BPC-157 sometimes target immune reconstitution and gut-mucosal repair concurrently, though each addition compounds the off-label nature of the protocol.

AOD-9604 Dosing Protocol for Post-COVID Recovery

The following protocol reflects practitioner consensus from functional and integrative medicine clinicians as synthesized by the HealthRX medical team. It is not derived from a published long-COVID trial. Treating physicians should adapt dose and duration to individual patient labs, symptom burden, and comorbidities.

Starting Dose and Titration

Most practitioners initiate AOD-9604 at 250 mcg per day subcutaneously for the first two weeks. If tolerability is confirmed (no injection-site reactions, no blood glucose disturbance, no worsening fatigue), the dose may be increased to 500 mcg per day. Some protocols extend to 1,000 mcg daily for patients with significant metabolic dysfunction, though this exceeds the dose range studied in published human trials and carries higher uncertainty [1].

The original Metabolic Pharmaceuticals phase II data used oral dosing at 1 mg/day, but subcutaneous delivery is standard in current compounding pharmacy protocols because subcutaneous bioavailability is substantially higher than oral for peptides of this molecular weight.

Administration Timing

Administer on an empty stomach, at least 30 minutes before the first meal of the day or 30 to 60 minutes before structured aerobic exercise. Fasted administration reduces competition with elevated insulin, which could theoretically blunt the peptide's interaction with adipose tissue receptors. This timing recommendation parallels guidance used for other lipolytic peptides and GH secretagogues, though no AOD-9604-specific pharmacokinetic study in humans has confirmed it [8].

Injection Technique

• Draw into a 1 mL insulin syringe (29 to 31 gauge, 5/16-inch needle).
• Rotate injection sites among abdomen, lateral thigh, and deltoid subcutaneous fat.
• Reconstitute lyophilized AOD-9604 with bacteriostatic water to a concentration of 2 mg/mL (2,000 mcg/mL), stored at 2 to 8°C and used within 30 days of reconstitution.
• Discard any vial showing particulate matter or discoloration.

Cycle Length and Washout

Run AOD-9604 for 8 to 12 weeks continuously, then take a 4-week washout before re-evaluating and potentially re-dosing. This cycle structure mirrors GH secretagogue protocols used for metabolic and recovery indications and prevents receptor desensitization, though AOD-9604's exact receptor dynamics in humans are not fully characterized.

Monitoring Labs and Safety Checkpoints

No specific monitoring protocol for AOD-9604 exists in published guidelines. The following is adapted from general peptide therapy safety frameworks and the specific pathophysiology of long-COVID.

Baseline Labs (Before Initiating)

Obtain these before the first injection:

• Complete metabolic panel (CMP) including fasting glucose and liver enzymes
• CBC with differential to evaluate baseline immune status
• Fasting insulin and HOMA-IR to quantify insulin sensitivity
• IGF-1 to rule out pre-existing GH-axis abnormality
• High-sensitivity CRP and ferritin as inflammatory markers
• D-dimer given persistent coagulopathy risk in long-COVID [9]
• AM cortisol to assess HPA-axis status, which is often blunted in long-COVID
• Thyroid panel (TSH, free T3, free T4) because thyroid dysfunction occurs in roughly 15% of long-COVID patients at six months [10]

Week 4 Interim Check

At four weeks, reassess fasting glucose, fasting insulin, and CRP. Patients with worsening glycemic markers should reduce dose or discontinue. AOD-9604 is not expected to alter IGF-1 appreciably (this distinguishes it from full hGH), but an IGF-1 check at week 4 confirms there is no unexpected somatotropic stimulation from the compound or from concurrent secretagogues.

End-of-Cycle Assessment (Week 8 to 12)

Repeat the full baseline panel. Add a symptom severity questionnaire such as the Post-COVID Functional Status (PCFS) scale to quantify change objectively. Body composition via DEXA or bioimpedance is appropriate if fat loss or lean mass preservation is a stated goal.

Safety Signals Warranting Immediate Discontinuation

• New or worsening edema
• Fasting glucose exceeding 126 mg/dL on two consecutive readings
• Any injection-site abscess
• Onset of joint pain or carpal tunnel symptoms (which would suggest unexpected IGF-1 elevation, possibly from an adulterant in the compound)
• Significant liver enzyme elevation (more than three times the upper limit of normal)

Expected Timeline of Outcomes

Anecdotal practitioner reports suggest the following rough trajectory. These are not validated endpoints from controlled trials.

Weeks 1 to 4: Foundation Phase

Patients typically report little subjective change. Injection tolerance is established. Some notice modest appetite regulation. Fatigue scores may remain unchanged or briefly worsen as the body adjusts. This mirrors observations in GH-axis peptide protocols where the first four weeks are mechanistically active but experientially quiet.

Weeks 4 to 8: Early Response Window

If response occurs, subjective energy improvement and reduced post-exertional malaise are typically the first signals. Body composition changes (mild reduction in truncal adiposity) may become measurable by bioimpedance. Sleep quality improvement has been noted in some functional medicine case reports, possibly related to normalization of nocturnal GH pulsatility patterns rather than direct AOD-9604 action.

Weeks 8 to 12: Consolidation Phase

Responders show stabilized or continued improvement in fatigue, cognitive clarity, and exercise tolerance. Non-responders should prompt re-evaluation of the underlying long-COVID pathophysiology driving symptoms. Persistent spike protein antigenemia, undiagnosed mast cell activation syndrome, or POTS may require targeted intervention before metabolic peptide support becomes effective.

Combining AOD-9604 With Other Long-COVID Interventions

AOD-9604 is rarely used as a monotherapy for long-COVID in current functional medicine practice. The HealthRX medical team does not endorse combination protocols without individual physician evaluation, but the rationale for common pairings is worth understanding.

AOD-9604 and BPC-157

BPC-157 (body protection compound) has published animal data supporting gut mucosal repair, angiogenesis, and tendon healing [11]. Long-COVID patients with significant gastrointestinal symptoms or joint pain are sometimes prescribed both peptides concurrently. There are no human trial data on this combination.

AOD-9604 and Thymosin Alpha-1

Thymosin alpha-1 (Ta1) is an immune-modulating peptide with published data in chronic viral infections. A 2021 systematic review in Frontiers in Pharmacology identified Ta1 as a candidate for COVID-19-associated immune dysregulation [12]. Some practitioners layer Ta1 with AOD-9604 to address immune reconstitution while AOD-9604 targets metabolic recovery. These are distinct mechanisms with distinct receptor targets, and no interaction data exist.

AOD-9604 and Lifestyle Interventions

Structured aerobic exercise (starting at 50 to 60% VO2max, 20 to 30 minutes three times per week) is the single most evidence-supported intervention for long-COVID fatigue in patients who tolerate it, per the 2023 Cochrane review on rehabilitation for post-COVID condition [13]. AOD-9604's proposed lipolytic and metabolic effects are likely amplified when combined with exercise rather than substituted for it. Practitioners should screen for POTS before prescribing exercise protocols, as orthostatic intolerance is present in up to 30% of long-COVID patients with fatigue [14].

Regulatory Status and Compounding Considerations

AOD-9604 is not FDA-approved for any indication. In the United States, it was previously on the FDA's 503A and 503B compounding pharmacy lists as a permissible bulk drug substance, but the FDA has moved to restrict peptide compounding categories iteratively since 2023. Prescribers must verify current compounding status with their pharmacy before initiating any protocol. The FDA's current guidance on bulk drug substances for compounding is available at accessdata.fda.gov [15].

Patients sourcing AOD-9604 from unregulated online vendors risk receiving adulterated or mis-dosed product. A 2018 analysis of research peptides purchased online found that 45 of 54 samples (83%) contained incorrect peptide concentration, wrong peptide identity, or bacterial contamination [16]. Physician-supervised protocols through licensed compounding pharmacies verified by PCAB accreditation substantially reduce this risk.

What the Evidence Does Not Support

Some online forums and peptide communities claim AOD-9604 directly repairs mitochondria, reverses spike-protein-induced endothelial damage, or eliminates brain fog within days. None of these claims has been tested in a controlled human trial. The honest clinical position is that AOD-9604's published human evidence base covers metabolic (anti-obesity) outcomes, the long-COVID application is mechanistically plausible but empirically unproven, and prescribers are operating in a clinically informed but data-sparse space.

The 2024 NIH RECOVER Initiative, which has enrolled more than 17,000 long-COVID participants across 200 sites, has not included AOD-9604 in any registered intervention arm as of January 2025 [17]. Its absence from RECOVER does not preclude future study, but it confirms that AOD-9604 has not reached the threshold of evidence required for inclusion in an NIH-sponsored adaptive platform trial.

The Infectious Diseases Society of America's 2023 guidelines on post-COVID conditions state that "there are currently insufficient data to recommend any specific pharmacological agent for the treatment of post-COVID conditions beyond those addressing identified comorbidities" [18]. AOD-9604 falls outside guideline-supported therapy by this standard.

Patient Selection: Who May Be Appropriate

Given the evidence gaps, AOD-9604 for long-COVID should be considered only within a physician-supervised program and for patients who meet criteria such as:

• Confirmed long-COVID diagnosis per WHO criteria (symptoms greater than 12 weeks post-acute infection) [2]
• Documented metabolic dysfunction (elevated fasting insulin, visceral adiposity on imaging, or abnormal DEXA composition)
• Failure of or inability to tolerate standard rehabilitative approaches
• No contraindications: active malignancy, pregnancy, lactation, uncontrolled type 2 diabetes (HbA1c above 9%), or prior hypersensitivity reaction to peptide compounds
• Age 18 or older (no pediatric data exist)
• Willing to complete baseline and follow-up labs and attend scheduled follow-up visits

Patients with purely respiratory long-COVID symptoms (persistent dyspnea, reduced DLCO on pulmonary function testing) are unlikely to derive primary benefit from AOD-9604 and should be prioritized for pulmonary rehabilitation and specialist evaluation.